Opportunity Information: Apply for RFA DA 20 020
Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional), funding opportunity number RFA-DA-20-020, is a National Institutes of Health (NIH) small business grant opportunity designed to push forward practical, commercially viable technologies that strengthen how communities use wastewater testing to monitor illicit drug use in near real time. The central idea is to treat wastewater monitoring as a smart-city public health tool: instead of relying only on traditional indicators like surveys, overdose reports, or law enforcement data (which can be delayed or incomplete), applicants are encouraged to develop methods and systems that can measure drug signals in wastewater and translate those measurements into timely, actionable intelligence about changing drug patterns.
The opportunity is structured under the SBIR Phased Innovation mechanism, using the R41/R42 activity codes. In general terms, Phase I (R41) supports early feasibility and proof-of-concept work, while Phase II (R42) supports further development, validation, and steps toward commercialization. The “Clinical Trial Optional” label signals that a clinical trial is not required for eligibility, but certain kinds of human-subjects or clinical-trial-like components could be proposed if they legitimately fit the research plan and meet NIH requirements. That said, most wastewater-based epidemiology projects focus on environmental sampling and analytics rather than clinical interventions, so applicants would typically emphasize technology development, validation, and implementation in real-world municipal contexts.
From a technology standpoint, NIH is looking for innovations that improve the utilization of wastewater testing for dynamic monitoring of illicit drugs. That can include better sampling approaches (for example, methods that increase representativeness over time or across neighborhoods), improved analytical chemistry and detection workflows (such as more sensitive, specific, faster, or cheaper assays for drug metabolites), data processing and interpretation platforms (including software that converts lab measurements into estimates and trends), and integrated systems that connect sampling, lab analysis, and reporting in a way that supports rapid public health decision-making. The emphasis on “smart city tools” suggests a strong interest in solutions that can be deployed at scale, operate continuously or frequently, and produce outputs that local officials can interpret and use quickly, such as dashboards, automated alerts, or decision-support systems. Because the announcement highlights commercialization potential, applicants are expected to articulate a credible path to market, including who the customers are (for example, municipal utilities, public health departments, state agencies, or service providers), what the adoption barriers are, and how the product would be sustained beyond the grant.
Eligibility is limited to small businesses, consistent with the SBIR program’s intent to stimulate technological innovation in the private sector. The notice also makes clear that non-U.S. (foreign) institutions are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components as defined in the NIH Grants Policy Statement may be allowed, meaning a U.S.-based applicant might be able to include certain foreign collaborations or activities if they meet NIH’s definition and are appropriately justified, but the applying organization itself must be a qualifying U.S. small business and the main project structure must remain compliant with NIH policy.
Administratively, this is a discretionary grant opportunity from NIH, aligned with the health mission area and identified under CFDA number 93.279 (drug abuse and related research). The opportunity’s original closing date was 2019-08-07, with a creation date of 2019-05-15, indicating it was posted for a specific funding cycle. While the provided data do not list an award ceiling or expected number of awards, the SBIR format typically involves milestone-based progress from feasibility to development, and applicants would be expected to budget and plan accordingly across phases, including clear technical milestones, validation plans, and deliverables that support eventual commercialization.
In practical terms, a strong proposal under this announcement would read like a product-focused R and D plan: it would identify a concrete problem with current wastewater drug monitoring (for example, slow turnaround times, inconsistent sampling, limited detection of emerging synthetic drugs, difficulty translating measurements into neighborhood-level signals, high operational cost, or lack of standardized reporting), propose a technology that measurably improves performance, and show how it could be adopted by real municipal stakeholders. The overall goal is to help communities detect and respond to shifts in illicit drug use faster and more accurately, using wastewater as a scalable, population-level signal that can complement other public health and public safety data sources.Apply for RFA DA 20 020
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2019-05-15.
- Applicants must submit their applications by 2019-08-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional) - RFA-DA-20-020
What is this funding opportunity?
Rapid Assessment of Drug Abuse: Smart City Tools (R41/R42 - Clinical Trial Optional) is an NIH small business grant opportunity focused on advancing practical, commercially viable technologies that improve how communities use wastewater testing to monitor illicit drug use in near real time. The funding opportunity number is RFA-DA-20-020.
What problem is NIH trying to solve with this opportunity?
The opportunity targets gaps in traditional indicators of drug use (such as surveys, overdose reports, or law enforcement data) that can be delayed, incomplete, or hard to interpret quickly. NIH is encouraging tools that treat wastewater monitoring as a smart-city public health capability, producing timely and actionable intelligence about changing drug patterns.
What does "smart city tools" mean in this context?
In this announcement, "smart city tools" points to solutions that can be deployed at scale, run continuously or at high frequency, and deliver outputs local decision-makers can use quickly. Examples include integrated systems connecting sampling, lab analysis, and reporting, as well as dashboards, automated alerts, and decision-support tools.
What types of projects are encouraged?
Projects are encouraged if they improve the utilization of wastewater testing for dynamic monitoring of illicit drugs. The announcement highlights technology development, validation, and real-world implementation in municipal contexts, with a strong emphasis on commercialization potential.
What kinds of technologies fit this opportunity?
NIH is looking for innovations across the wastewater monitoring workflow, including:
- Sampling approaches that improve representativeness over time or across neighborhoods
- Analytical chemistry and detection workflows (more sensitive, specific, faster, or lower-cost assays for drug metabolites)
- Data processing and interpretation platforms that convert measurements into estimates and trends
- Integrated systems that connect sampling, lab analysis, and reporting for rapid decision-making
Is this opportunity focused on research, product development, or both?
Both, but with a product-oriented framing. A strong proposal is expected to read like a product-focused R&D plan: identify a specific operational or technical problem in wastewater drug monitoring, propose a measurable improvement, validate performance, and show how it can be adopted and sustained beyond the grant through commercialization.
What do the R41 and R42 activity codes mean?
This opportunity uses the SBIR Phased Innovation mechanism. In general terms:
- Phase I (R41) supports early feasibility and proof-of-concept work.
- Phase II (R42) supports further development, validation, and steps toward commercialization.
What does "Clinical Trial Optional" mean?
"Clinical Trial Optional" means a clinical trial is not required to apply, but certain human-subjects or clinical-trial-like components could be proposed if they legitimately fit the research plan and meet NIH requirements. Many wastewater-based epidemiology projects focus on environmental sampling and analytics rather than clinical interventions, so proposals often emphasize technology development and implementation instead of clinical trials.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with the SBIR program's goal of stimulating private-sector technological innovation.
Are non-U.S. (foreign) organizations eligible to apply?
No. Non-U.S. (foreign) institutions are not eligible to apply. In addition, non-U.S. components of U.S. organizations are not eligible to apply.
Are any foreign collaborations allowed?
Foreign components (as defined in the NIH Grants Policy Statement) may be allowed. That means a U.S.-based applicant might be able to include certain foreign collaborations or activities if they meet NIH's definition and are appropriately justified. The applicant organization still must be a qualifying U.S. small business, and the main project structure must remain compliant with NIH policy.
What is the expected use case for the funded technology?
The expected use case is near-real-time monitoring of illicit drug trends using wastewater as a population-level signal, enabling communities to detect and respond to shifts in drug use faster and more accurately. Outputs are expected to be usable by local stakeholders for rapid public health decision-making.
Who are the likely customers or end users for products developed under this funding?
The announcement points to potential customers such as municipal utilities, public health departments, state agencies, and service providers. Applicants are expected to identify who would buy and use the product and why.
What kinds of outputs or deliverables are implied by the announcement?
While specific deliverables are not listed in the provided text, the announcement emphasizes clear technical milestones, validation plans, and outputs that support commercialization. Examples implied by the "smart city" framing include standardized reporting, dashboards, automated alerts, and integrated sampling-to-reporting systems.
What makes a proposal "strong" under this announcement?
Based on the information provided, a strong proposal would:
- Identify a concrete limitation in current wastewater drug monitoring (for example, slow turnaround, inconsistent sampling, limited detection of emerging synthetic drugs, difficulty translating measurements into neighborhood-level signals, high operational cost, or lack of standardized reporting).
- Propose a technology that measurably improves performance (speed, sensitivity, specificity, cost, frequency, scalability, or interpretability).
- Include a plan for validation and implementation in real municipal contexts.
- Present a credible commercialization path, including customers, adoption barriers, and sustainability beyond the grant.
How does this opportunity relate to commercialization?
Commercialization is a central theme. Applicants are expected to articulate a credible path to market, including identification of customer segments, adoption barriers, and how the product would be sustained after the grant period.
What NIH mission area is this opportunity aligned with?
It is an NIH discretionary grant opportunity aligned with drug abuse and related research.
What is the CFDA number associated with this opportunity?
The CFDA number provided is 93.279 (drug abuse and related research).
When was this opportunity created and when did it close?
The creation date provided is 2019-05-15. The original closing date provided is 2019-08-07, indicating it was posted for a specific funding cycle.
Does the provided information include an award ceiling or expected number of awards?
No. The provided information does not list an award ceiling or the expected number of awards.
How should applicants think about planning and budgeting across phases?
The text notes that SBIR projects typically move milestone-by-milestone from feasibility to development. Applicants are expected to budget and plan accordingly across phases, including clear technical milestones, validation plans, and commercialization-supporting deliverables.
What is the core data source these tools are built around?
The core data source is wastewater testing for illicit drugs and/or drug metabolites, used as a scalable, population-level signal that can complement other public health and public safety data sources.
What types of improvements to turnaround time are relevant here?
The opportunity emphasizes near-real-time and rapid decision-making, so improvements that reduce delays across sampling, analysis, and reporting are directly relevant. The announcement also highlights integrated systems and automated reporting as examples of rapid-use outputs.
Is the goal to replace traditional indicators of drug use?
No. The description frames wastewater monitoring as a complement to traditional indicators like surveys, overdose reports, or law enforcement data, especially because those sources can be delayed or incomplete.
Browse more opportunities from the same category: Education, Health
Next opportunity: Population Dynamics Centers Research Infrastructure Program FY 2020 (P2C Clinical Trial Not Allowed)
Previous opportunity: Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 20 020
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 20 020) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 19 282 Funding Number: PAR 19 282 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Rapid Assessment of Drug Abuse: Smart City Tools (R43/R44 - Clinical Trial Optional) Apply for RFA DA 20 021 Funding Number: RFA DA 20 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional) Apply for RFA DA 20 013 Funding Number: RFA DA 20 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Workshops on the Use of Adolescent Brain Cognitive Development (ABCD) Data (R25 Clinical Trial Not Allowed) Apply for RFA DA 20 001 Funding Number: RFA DA 20 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional) Apply for PAR 19 287 Funding Number: PAR 19 287 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| The Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network - Clinical Sites (U01 Clinical Trial Required) Apply for RFA HG 19 013 Funding Number: RFA HG 19 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed) Apply for RFA DA 20 019 Funding Number: RFA DA 20 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional ) Apply for RFA DA 20 016 Funding Number: RFA DA 20 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $550,000 |
| NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 19 290 Funding Number: PAR 19 290 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) Apply for PAR 19 291 Funding Number: PAR 19 291 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Clinical Outcome Assessments for Clinical Trials in Substance Use Disorders as FDA-qualified Drug Development Tools (U01 Clinical Trial Optional) Apply for RFA DA 20 015 Funding Number: RFA DA 20 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 - Clinical Trials Not Allowed) Apply for RFA DA 20 009 Funding Number: RFA DA 20 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 - Clinical Trials Not Allowed) Apply for RFA DA 20 008 Funding Number: RFA DA 20 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01 Clinical Trial Not Allowed) Apply for RFA CA 19 055 Funding Number: RFA CA 19 055 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required) Apply for RFA CA 19 031 Funding Number: RFA CA 19 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) Apply for PAR 19 309 Funding Number: PAR 19 309 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional) Apply for PAR 19 310 Funding Number: PAR 19 310 Agency: National Institutes of Health Category: Education, Health Funding Amount: $75,000 |
| Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R01 - Clinical Trials Not Allowed) Apply for RFA DA 20 006 Funding Number: RFA DA 20 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance Use Disorder (R21 - Clinical Trials Not Allowed) Apply for RFA DA 20 007 Funding Number: RFA DA 20 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed) Apply for RFA DA 20 023 Funding Number: RFA DA 20 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 20 020", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.